Welcome
Support Centre
02 September 2010 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Pilot Effectiveness of Randomised Mandatory Insulin Therapy
ISRCTN ISRCTN00550641
ClinicalTrials.gov identifier
Public title Pilot Effectiveness of Randomised Mandatory Insulin Therapy
Scientific title
Acronym PERMIT study
Serial number at source N/A
Study hypothesis As of 23/07/2009 this record was extensively updated to include changes that took place to the protocol before trial completion. All updates can be found under the relevant section with the above update date.

Current information as of 23/07/2009:
In patients requiring more than 48 hours of critical care treatment, mandatory insulin therapy, in comparison to usual sliding scale insulin therapy will not alter glycaemic control (including the number of severe hypoglycaemic events), but will modulate the derangements in the somatotrophic axis seen in critically ill patients.

Initial information at time of registration:
In patients requiring 5 or more days of critical care treatment, giving mandatory insulin therapy, compared to usual sliding scale insulin therapy as required, the number of severe hypoglycaemic events will be unchanged.
Ethics approval Added 23/07/2009: Oxford Research Ethics Committee (REC) C approved (ref: 05/Q1606/103)
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Intensive care admission
Participants - inclusion criteria Current information as of 23/07/2009:
Adult patients likely to remain on the intensive care unit (ICU) for greater than 48 hours.

Initial information at time of registration:
Adult patients likely to remain on the intensive care unit (ICU) for greater than 5 days
Participants - exclusion criteria 1. Patients known to have diabetes mellitus
2. Patients admitted with diabetic ketoacidosis
3. Patients with a current diagnosis of pancreatitis
4. Patients who have undergone hepato-biliary surgery in the current admission
5. Patients with an insulinoma or pituitary tumour
6. Patients currently on, or likely to require, total parenteral nutrition
7. Patients who are pregnant
8. Patients with a primary diagnosis of head injury
9. Patients with a primary diagnosis of intracranial haemorrhage
10. Patients with a primary diagnosis of stroke
11. Inclusion in another study
12. Patients currently placed under a section order
13. Patients with a learning disability
14. Patients/relatives unable to speak English and without a suitable translator
15. Patients already on higher than 4 units of insulin per hour and have been so for at least 3 out of the last 24 hours
Anticipated start date 01/07/2005
Anticipated end date 30/06/2006
Status of trial Completed
Patient information material
Target number of participants 120
Interventions Sliding scale insulin versus mandated insulin
Primary outcome measure(s) Current information as of 23/07/2009:
1. Glycaemic control (measured as proportion of hyperglycaemic time, number of severe hypoglycaemic episodes per patient).
2. Effects on the somatotrophic axis

Initial information at time of registration:
Number of episodes of hypoglycaemia per unit length of stay in the ICU.
Secondary outcome measure(s) Current information as of 23/07/2009:
1. Biochemical markers:
1.1. The number of patients undergoing a hypoglycaemic episode and the number of hypoglycaemic episodes whilst receiving the study protocol
1.2. The number of patients undergoing a hypokalaemic episode and the number of hypokalaemic episodes whilst receiving the study protocol
1.3. Plasma concentrations of IGF-1, IGF-2, IGFBP-1, IGFBP-3, GH at baseline and on days 3,5, 8 and 15 of ICU stay
1.4. Plasma concentrations of HDL, LDL, TG's, FFA's at baseline and at days 3, 5 and 8 and 15 of ICU stay
1.5. The difference between nitrogen excretion (as urinary urea) and nitrogen intake (as enteral or parenteral nutrition) on days 3, 5 and 8 of ICU stay
1.6. Plasma protein carbonyl quantification on days 1, 3, 5, 8 and 15 of ICU stay

2. Morbidity and mortality:
2.1. ICU length of stay
2.2. Antibiotic free days
2.3. 30 day mortality

3. Markers of protocol compliance:
3.1. Time-weighted average blood glucose concentration
3.2. Time-weighted average serum potassium concentration
3.3. Time-weighted average insulin infusion and total insulin delivered

Initial information at time of registration:
1. Biochemical markers:
1.1. The number of episodes of hypokalaemia per unit length of stay in the ICU
1.2. The plasma levels of IGF-1, IGFBP-1, IGFBP-3, ALS on days 1, 3, 5, 8 and 15 of ICU stay
1.3. The plasma HDL, LDL and triglycerides on days 1, 3, 5, 8 and 15 of ICU stay
1.4. The plasma levels of free fatty acids on days 1, 3, 5, 8 and 15 of ICU stay
1.5. The difference between nitrogen excretion (as urinary urea) and nitrogen intake (as enteral or parenteral nutrition) on days 1, 3, 5, 8 and 15 of ICU stay
1.6. Plasma protein carbonyl quantification on days 1, 3, 5, 8 and 15 of ICU stay

2. Surrogate markers for improved long term outcome:
2.1. ICU length of stay
2.2. Hospital length of stay
2.3. Antibiotic free days (as a measure of nosocomial infection)

3. Mortality:
3.1. ICU mortality
3.2. 30 day mortality
3.3. Hospital mortality

4. Markers of protocol compliance:
4.1. Time-weighted average blood glucose concentration
4.2. Time-weighted average serum potassium concentration
4.3. Time-weighted average insulin infusion and total insulin delivered
Sources of funding British Journal of Anaesthesia/Royal College of Anaesthetists (UK)
Trial website
Publications
Contact name Dr  J Duncan  Young
  Address Adult Intensive Care Unit
John Radcliffe Hospital
Headley Way
  City/town Oxford
  Zip/Postcode OX3 9DU
  Country United Kingdom
Sponsor Oxford Radcliffe Hospitals NHS Trust (UK)
  Address Research & Development Department
Manor House
John Radcliffe Hospital
Headley Way
  City/town Oxford
  Zip/Postcode OX3 9DU
  Country United Kingdom
Date applied 23/05/2005
Last edited 04/08/2009
Date ISRCTN assigned 21/07/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2010 ISRCTN unless otherwise stated.


BioMed Central